Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187202 | 1.00 | GPR119 (0.41) | GPR119PTPN1CHRM2NR1H2HSD11B1 | |
| SCHEMBL31341756 | 0.83 | GPR119 (0.44) | GPR119PTPN1NR1H2HSD11B1USP2 | |
| SCHEMBL20187135 | 0.82 | CHRM2 (0.43) | CHRM2HSD11B1DPP4 | |
| SCHEMBL9965879 | 0.81 | GPR119 (0.43) | GPR119PTPN1CHRM2NR1H2HSD11B1 | |
| SCHEMBL16182173 | 0.81 | GPR119 (0.43) | GPR119PTPN1CHRM2NR1H2HSD11B1 | |
| SCHEMBL12836453 | 0.81 | GPR119 (0.43) | GPR119PTPN1CHRM2NR1H2HSD11B1 | |
| SCHEMBL661532 | 0.77 | HSD11B1 (0.55) | GPR119PTPN1HSD11B1PDE4BSMN1; SMN2 | |
| SCHEMBL2899012 | 0.76 | GPR119 (0.53) | GPR119HSD11B1USP2SMN1; SMN2 | |
| SCHEMBL10163212 | 0.76 | HSD11B1 (0.49) | GPR119HSD11B1SMN1; SMN2 | |
| SCHEMBL13779791 | 0.73 | NR1H2 (0.54) | GPR119CHRM2NR1H2RORCUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849044-B | Triaza-spirodecanones as DDR1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | GPR119 1418/4885PTPN1 239/4885CHRM2 3315/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | GPR119 1418/4885PTPN1 239/4885CHRM2 3315/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | GPR119 1418/4885PTPN1 239/4885CHRM2 3315/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | GPR119 1418/4885PTPN1 239/4885CHRM2 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.